Citi Questions Whether Moderna’s Melanoma Vaccine Benefit Justifies Manufacturing

Citi called Moderna’s melanoma vaccine results a “clinically meaningful advance” but questioned whether the benefit justifies individualized tumor harvesting and manufacturing.